CymaBay Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- CymaBay Therapeutics's estimated annual revenue is currently $6.8M per year.
- CymaBay Therapeutics received $Undisclosed in venture funding in January 2018.
- CymaBay Therapeutics's estimated revenue per employee is $56,016
- CymaBay Therapeutics's total funding is $276M.
- CymaBay Therapeutics's current valuation is $266.7M. (January 2022)
Employee Data
- CymaBay Therapeutics has 122 Employees.
- CymaBay Therapeutics grew their employee count by 61% last year.
CymaBay Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | VP, Manufacturing and Supply Chain Operations | Reveal Email/Phone |
3 | VP, Clinical Development | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | SVP Business Development | Reveal Email/Phone |
6 | VP Market Access | Reveal Email/Phone |
7 | VP Finance | Reveal Email/Phone |
8 | SVP, Human Resources | Reveal Email/Phone |
9 | VP Commercial Operations | Reveal Email/Phone |
10 | VP Nonclinical Development and Project Management | Reveal Email/Phone |
CymaBay Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is CymaBay Therapeutics?
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH). For additional information about CymaBay visit www.cymabay.com.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$276M
Total Funding
122
Number of Employees
$6.8M
Revenue (est)
61%
Employee Growth %
$266.7M
Valuation
N/A
Accelerator
CymaBay Therapeutics News
Equities research analysts predict that CymaBay Therapeutics, Inc. (NASDAQ:CBAY Get Rating) will announce earnings per share (EPS) of...
Hence, if weakness in CymaBay Therapeutics' share price continues, institutional investors may feel compelled to sell the stock, which might not...
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic...
A little over a year after resurrecting the liver disease drug seladelpar, CymaBay Therapeutics now has $100 million to bankroll a phase 3 study of the drug. RELATED: CymaBay resurrects seladelpar 8 months after NASH flop In November, the Newark, California-based biopharma presented data showi ...
Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC CymaBay retains full worldwide commercial rights to seladelpar NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company ...
Other Companies in Newark
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 123 | 10% | N/A |
#2 | $17.8M | 123 | -5% | N/A |
#3 | $18.1M | 125 | 23% | N/A |
#4 | $90M | 126 | 4% | $15.9M |
#5 | $43M | 131 | 18% | N/A |
CymaBay Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-10-21 | $26.8M | Undisclosed | Article | |
| 2015-08-18 | $325.0M | Undisclosed | Article | |
| 2018-01-31 | $Undisclosed | Undisclosed | Leerink Partners LLC | Article |